J&J's COVID-19 Vaccine Shows Rare Events, Now Paused
We expect the pause to be temporary because of the rarity of the adverse events—six cases among the more than 6.8 million doses administered in the U.S.
The U.S. Centers for Disease Control and Prevention and the Food and Drug Administration have recommended a pause in using Johnson & Johnson's (JNJ) COVID-19 vaccine due to a handful of cases of severe blood clots among Americans receiving the vaccine. We don’t expect any changes to our $158 fair value estimate or wide moat rating for J&J, as the vaccine is being delivered on a not-for-profit basis.
Further, we expect the pause to be temporary because of the rarity of the adverse events—six cases among the more than 6.8 million doses administered in the U.S. However, this development could slightly disrupt the timing of herd immunity in the U.S. and have bigger effects on a return to normal in international markets relying more heavily on adenoviral vector vaccines from Johnson & Johnson and AstraZeneca.
The potential side effects related to the J&J vaccine appear very rare and are likely surmountable. But the severity is concerning. The U.S. government agencies plan to review the data and provide updated guidance, which we expect over the next couple of weeks. Also, the European rollout will probably be delayed until more clarity is established. The potential side effects with the J&J vaccine seem to match similar rare side effects of AstraZeneca’s COVID-19 vaccine, which is based on similar vector technology and could therefore lead to age restrictions on its administration.
Under the worst-case scenario where the J&J vaccine is removed from the market, we believe enough alternative vaccines are available to only slightly delay herd immunity in the U.S. from early June to late June. However, globally, the potential loss of the vaccine would be more pronounced, given the ease of one-dose delivery and easier storage conditions. We see the J&J vaccine holding the most importance in developing markets that lack strong healthcare distribution infrastructure.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.